Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danicopan in GA secondary to AMD
NCT05019521Phase 2Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Aug 2021
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial of danicopan in geographic atrophy (GA) (4 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Rate of Change From Baseline to Week 52 in the Square Root of Total Geographic Atrophy Lesion Area. Started Aug 2021; status: terminated.
02
Drugs
danicopan
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT05019521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05019521.